Cat. No：GM-C19834
Product：H_FGF21 Reporter HEK-293 Cell Line
Cat. No：GM-C19834
Product：H_FGF21 Reporter HEK-293 Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+0.75 μg/mL Puromycin+125 μg/mL Hygromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Fibroblast growth factor 21 (FGF21) is an endocrine member of the FGF superfamily along with FGF19 and FGF23. It has been shown to act as a metabolic regulator, playing a role in controlling glucose homeostasis, insulin sensitivity, and ketogenesis. The liver is considered the main site of FGF21 production, where it is released into the bloodstream. Additionally, extrahepatic tissues such as white and brown adipose tissue and skeletal muscle also express FGF21.
The action of FGF21 on target cells requires FGFRs and β-Klotho, a single-pass transmembrane protein that acts as a receptor component for FGF21 signal transduction. When these two bind together, FGF21 stimulates insulin sensitivity and glucose metabolism, resulting in weight loss. Treatment with FGF21 or overexpression of FGF21 in vivo can reduce the risk of obesity, high insulinemia, insulin resistance, and hyperglycemia in rodents, monkeys, and humans.
Genomeditech H_FGF21 Reporter HEK-293 Cell Line is a Luciferase reporter gene cell line. Upon binding of FGF21 to FGFR1 and β-Klotho (KLB) receptors, downstream signaling pathways are activated, leading to the expression of luciferase. The luciferase readings represent the activation effect of the signaling pathway and can be used for the in vitro evaluation of FGF21-related drugs.
Cat. No：GM-C19834
Product：H_FGF21 Reporter HEK-293 Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+0.75 μg/mL Puromycin+125 μg/mL Hygromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Fibroblast growth factor 21 (FGF21) is an endocrine member of the FGF superfamily along with FGF19 and FGF23. It has been shown to act as a metabolic regulator, playing a role in controlling glucose homeostasis, insulin sensitivity, and ketogenesis. The liver is considered the main site of FGF21 production, where it is released into the bloodstream. Additionally, extrahepatic tissues such as white and brown adipose tissue and skeletal muscle also express FGF21.
The action of FGF21 on target cells requires FGFRs and β-Klotho, a single-pass transmembrane protein that acts as a receptor component for FGF21 signal transduction. When these two bind together, FGF21 stimulates insulin sensitivity and glucose metabolism, resulting in weight loss. Treatment with FGF21 or overexpression of FGF21 in vivo can reduce the risk of obesity, high insulinemia, insulin resistance, and hyperglycemia in rodents, monkeys, and humans.
Genomeditech H_FGF21 Reporter HEK-293 Cell Line is a Luciferase reporter gene cell line. Upon binding of FGF21 to FGFR1 and β-Klotho (KLB) receptors, downstream signaling pathways are activated, leading to the expression of luciferase. The luciferase readings represent the activation effect of the signaling pathway and can be used for the in vitro evaluation of FGF21-related drugs.
